BC Extra | Jul 23, 2019
Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

Biogen will increasingly prioritize immunology and ophthalmology to better balance risk and reward within its pipeline, executives said during the company's quarterly call Tuesday. As the biotech reported earnings that generally beat expectations, management played...
BC Extra | Mar 4, 2019
Company News

Biogen to acquire ophthalmology gene therapy play Nightstar

Gene therapy platforms continue to capture the interest of large biopharma, with Biogen the latest to announce a deal. The bellwether said early Monday that it will acquire ophthalmology gene therapy company Nightstar for $877...
BC Week In Review | Oct 5, 2018
Financial News

Aldeyra, Nightstar price follow-ons

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Nightstar Therapeutics plc (NASDAQ:NITE) each priced follow-ons Sept. 27, raising a total of about $144 million. Aldeyra raised $72.2 million through the sale of 5.3 million shares at $13.75 in...
BC Extra | Sep 28, 2018
Financial News

Aldeyra, Nightstar price follow-ons

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Nightstar Therapeutics plc (NASDAQ:NITE) each priced follow-ons Thursday, raising a total of about $144 million. Aldeyra raised $72.2 million through the sale of 5.3 million shares at $13.75 in a...
BioCentury | Jun 14, 2018
Finance

Gene therapies in Sync

With the launch of a pair of new start-ups, Syncona Ltd. (LSE:SYNC) has invested in a CNS play and a new ophthalmic approach, bringing the U.K. firm’s gene therapy portfolio to five. Syncona invested $23...
BC Week In Review | Sep 8, 2017
Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to $86.3 million on Aug. 31 in an IPO on NASDAQ underwritten by Jefferies, Leerink, BMO Capital Markets, Wedbush...
BC Extra | Sep 1, 2017
Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to $86.3 million on Thursday in an IPO on NASDAQ underwritten by Jefferies, Leerink, BMO Capital Markets, Wedbush and...
BC Week In Review | Mar 23, 2017
Clinical News

AAV-XLRPGR: Ph I/II started

NightstaRx began an open-label, dose-escalation Phase I/II trial to evaluate single subretinal injections of AAV-XLRPGR in about 24 male patients. NightstaRx Ltd. , London, U.K.  Product: AAV-XLRPGR   Business: Ophthalmic  Molecular target: NA  Description: Adeno-associated viral...
Items per page:
1 - 8 of 8